Veracyte reports Q1 adjusted EPS 31c, consensus 20c

Reports Q1 revenue $114.5M, consensus $110.97M. “We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand,” said Marc Stapley, Veracyte’s (VCYT) chief executive officer. “With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in advancing our strategic growth drivers. As always, everything we do is in service of patients globally and I look forward to delivering on our vision of transforming cancer care.”